There are no long-term studies examining the safety of NR or NMN
The information in Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing
This phase, which can last for an extended period, may involve adjusting the tirzepatide dosage to help maintain your weight loss
doi: 10.1007/s10495-024-02043-3 129 CristoforiFDargenioVNDargenioCMinielloVLBaroneM
Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, Lambert A, Zhao ZZ, Roseman F, Guo Q, Gordon SD